Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market ...

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has ...

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

In this episode of Denatured, BioSpace's Head of Insights Lori Ellis talks to Dr. Peter Marks, Director, CBER, about his thoughts on the future of cell and gene therapies.

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to ...

A report published Tuesday shows hundreds and thousands of percent markups on HIV, hypertension and cancer drugs for Medicare ...

An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...